304 North Cardinal St.
Dorchester Center, MA 02124
Product Name: Alecinix
Generic Name: Alectinib
Brand Name: Alecensa
WeChat and WhatsApp: +8801304498958
Alectinib was approved for the treatment of ALK fusion-gene postive in japan in july 2014 for the treatment of recurrent, unresectable or advance non-small cell lung cancer and it was approved by FDA in 2015.
Alecinix150mg(Alectinib): Mechanism of Action
Alectinib is an oral medication classified as a tyrosine kinase inhibitor. It works by selectively targeting and blocking specific abnormal proteins, including anaplastic lymphoma kinase (ALK), which drives the growth of cancer cells. By inhibiting ALK, Alectinib hinders the proliferation and survival of cancerous cells.
Alecinix150mg(Alectinib): Side Effects
Alectinib may cause some side effects, which vary from patient to patient. Common side effects may include but are not limited to nausea, fatigue, diarrhea, constipation, muscle pain, and changes in appetite. It is important to consult with a healthcare professional for personalized guidance and management of side effects.
Alecinix150mg(Alectinib): Package insert
For comprehensive details on Alectinib’s administration, dosing, precautions, contraindications, and potential drug interactions, please refer to the official package insert provided by the manufacturer or consult your healthcare professional.
Alecinix150mg(Alectinib): Life Expectancy and Success Rate
Alectinib is an effective medicine that are being used since 2014 to treat anaplastic lymphoma kinase positive non-small cell lung cancer. Alectinib may increase the life expectency of patietn 34.8 month compared to Crizotinib which may increase 10.9 month.